Literature DB >> 24691437

Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.

Daniel Malouli, Scott G Hansen, Ernesto S Nakayasu, Emily E Marshall, Colette M Hughes, Abigail B Ventura, Roxanne M Gilbride, Matthew S Lewis, Guangwu Xu, Craig Kreklywich, Nathan Whizin, Miranda Fischer, Alfred W Legasse, Kasinath Viswanathan, Don Siess, David G Camp, Michael K Axthelm, Christoph Kahl, Victor R DeFilippis, Richard D Smith, Daniel N Streblow, Louis J Picker, Klaus Früh.   

Abstract

The most abundantly produced virion protein in human cytomegalovirus (HCMV) is the immunodominant phosphoprotein 65 (pp65), which is frequently included in CMV vaccines. Although it is nonessential for in vitro CMV growth, pp65 displays immunomodulatory functions that support a potential role in primary and/or persistent infection. To determine the contribution of pp65 to CMV infection and immunity, we generated a rhesus CMV lacking both pp65 orthologs (RhCMVΔpp65ab). While deletion of pp65ab slightly reduced growth in vitro and increased defective particle formation, the protein composition of secreted virions was largely unchanged. Interestingly, pp65 was not required for primary and persistent infection in animals. Immune responses induced by RhCMVΔpp65ab did not prevent reinfection with rhesus CMV; however, reinfection with RhCMVΔUS2-11, which lacks viral-encoded MHC-I antigen presentation inhibitors, was prevented. Unexpectedly, induction of pp65b-specific T cells alone did not protect against RhCMVΔUS2-11 challenge, suggesting that T cells targeting multiple CMV antigens are required for protection. However, pp65-specific immunity was crucial for controlling viral dissemination during primary infection, as indicated by the marked increase of RhCMVΔpp65ab genome copies in CMV-naive, but not CMV-immune, animals. Our data provide rationale for inclusion of pp65 into CMV vaccines but also demonstrate that pp65-induced T cell responses alone do not recapitulate the protective effect of natural infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691437      PMCID: PMC4002596          DOI: 10.1172/JCI67420

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  79 in total

1.  Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.

Authors:  Stephen Mackinnon; Kirsty Thomson; Stephanie Verfuerth; Karl Peggs; Mark Lowdell
Journal:  Blood Cells Mol Dis       Date:  2007-09-14       Impact factor: 3.039

2.  Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68).

Authors:  T Somogyi; S Michelson; M J Masse
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

3.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

4.  Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain.

Authors:  Jenny Odeberg; Bodo Plachter; Lars Brandén; Cecilia Söderberg-Nauclér
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

5.  Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein.

Authors:  A Gallina; L Simoncini; S Garbelli; E Percivalle; G Pedrali-Noy; K S Lee; R L Erikson; B Plachter; G Gerna; G Milanesi
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  A new logic for DNA engineering using recombination in Escherichia coli.

Authors:  Y Zhang; F Buchholz; J P Muyrers; A F Stewart
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

Review 7.  Tegument proteins of human cytomegalovirus.

Authors:  Robert F Kalejta
Journal:  Microbiol Mol Biol Rev       Date:  2008-06       Impact factor: 11.056

8.  Spectral probabilities and generating functions of tandem mass spectra: a strike against decoy databases.

Authors:  Sangtae Kim; Nitin Gupta; Pavel A Pevzner
Journal:  J Proteome Res       Date:  2008-07-03       Impact factor: 4.466

9.  Replication of rhesus cytomegalovirus in life-expanded rhesus fibroblasts expressing human telomerase.

Authors:  W L William Chang; Veronica Kirchoff; Gregory S Pari; Peter A Barry
Journal:  J Virol Methods       Date:  2002-07       Impact factor: 2.014

10.  Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types.

Authors:  Anders E Lilja; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

View more
  20 in total

1.  Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.

Authors:  Ann J Hessell; Mariya B Shapiro; Rebecca Powell; Delphine C Malherbe; Sean P McBurney; Shilpi Pandey; Tracy Cheever; William F Sutton; Christoph Kahl; Byung Park; Susan Zolla-Pazner; Nancy L Haigwood
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 2.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

3.  The tegument protein pp65 of human cytomegalovirus acts as an optional scaffold protein that optimizes protein uploading into viral particles.

Authors:  Sabine Reyda; Stefan Tenzer; Pedro Navarro; Wolfgang Gebauer; Michael Saur; Steffi Krauter; Nicole Büscher; Bodo Plachter
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Authors:  Elizabeth C Swanson; Pete Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Megan Schmit; Jason C Zabeli; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2015-06-13       Impact factor: 3.641

Review 5.  The history of vaccination against cytomegalovirus.

Authors:  Stanley Plotkin
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

6.  Antagonism of the Protein Kinase R Pathway in Human Cells by Rhesus Cytomegalovirus.

Authors:  Stephanie J Child; Sarah E Hickson; Avraham Bayer; Daniel Malouli; Klaus Früh; Adam P Geballe
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

7.  Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.

Authors:  Emily E Marshall; Daniel Malouli; Scott G Hansen; Roxanne M Gilbride; Colette M Hughes; Abigail B Ventura; Emily Ainslie; Andrea N Selseth; Julia C Ford; David Burke; Craig N Kreklywich; Jennie Womack; Alfred W Legasse; Michael K Axthelm; Christoph Kahl; Daniel Streblow; Paul T Edlefsen; Louis J Picker; Klaus Früh
Journal:  Sci Transl Med       Date:  2019-07-17       Impact factor: 17.956

8.  Endothelial Cell Infection by Guinea Pig Cytomegalovirus Is a Lytic or Persistent Infection Depending on Tissue Origin but Requires Viral Pentamer Complex and pp65 Tegument Protein.

Authors:  K Yeon Choi; Nadia El-Hamdi; Alistair McGregor
Journal:  J Virol       Date:  2022-08-24       Impact factor: 6.549

9.  Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy.

Authors:  Daniel Malouli; Scott G Hansen; Meaghan H Hancock; Colette M Hughes; Julia C Ford; Roxanne M Gilbride; Abigail B Ventura; David Morrow; Kurt T Randall; Husam Taher; Luke S Uebelhoer; Matthew R McArdle; Courtney R Papen; Renee Espinosa Trethewy; Kelli Oswald; Rebecca Shoemaker; Brian Berkemeier; William J Bosche; Michael Hull; Justin M Greene; Michael K Axthelm; Jason Shao; Paul T Edlefsen; Finn Grey; Jay A Nelson; Jeffrey D Lifson; Daniel Streblow; Jonah B Sacha; Klaus Früh; Louis J Picker
Journal:  Sci Immunol       Date:  2021-03-25

10.  Guinea pig cytomegalovirus protective T cell antigen GP83 is a functional pp65 homolog for innate immune evasion and pentamer dependent virus tropism.

Authors:  K Yeon Choi; Nadia El-Hamdi; Julia Hornig; Alistair McGregor
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.